{"id":14351,"date":"2021-04-23T09:14:37","date_gmt":"2021-04-23T09:14:37","guid":{"rendered":"https:\/\/clinlabint.com\/?p=14351"},"modified":"2021-04-23T09:14:37","modified_gmt":"2021-04-23T09:14:37","slug":"bio-rad-launches-sars-cov-2-variant-rt-pcr-assays","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/bio-rad-launches-sars-cov-2-variant-rt-pcr-assays\/","title":{"rendered":"Bio-Rad launches SARS-CoV-2 variant RT-PCR assays"},"content":{"rendered":"

\"SARS-Cov_2<\/p>\n

Bio-Rad Laboratories has introduced SARS-CoV-2 Variant RT-PCR Assays for research use only (RUO). The assays can detect SARS-CoV-2 variants of concern, including P.1, B.1.351, and B.1.1.7, by distinguishing specific mutations using reverse transcription PCR (RT-PCR) often prior to a next generation sequencing (NGS) workflow for confirmation.<\/p>\n

With the emergence of several SARS-CoV-2 variants of concern, public health researchers are looking for a quicker way to track the spread of these variants in a population. Laboratories that use NGS to track COVID-19 variants can detect these mutations more quickly and cost-effectively with the SARS-CoV-2 Variant RT-PCR Assays to more rapidly prioritize which samples to submit for NGS.<\/p>\n